Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Open-market sale Director sold 47,652 shares at an average $41.31 ($1,968,352)
  4. 4 Option exercise Chief Scientific Officer acquired 6,500 shares (option exercise)
  5. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $50.98 ($135,087)
  6. 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $50.99 ($50,990)
  7. 4 Open-market sale Director sold 19,415 shares at an average $49.07 ($952,613)
  8. 4 Open-market sale Director sold 28,236 shares at an average $49.71 ($1,403,553)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Medical Officer sold 1,000 shares at $50.15 ($50,150)
  16. 4 Open-market sale Chief Scientific Officer sold 2,650 shares at $50.00 ($132,500)
  17. 4 Open-market sale Director sold 47,651 shares at an average $57.27 ($2,728,849)
  18. 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $59.93 ($59,926)
  19. 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $60.00 ($318,026)
  20. 4 Open-market sale Director sold 9,298 shares at an average $58.81 ($546,840)

Page 8 of 11 · 207 filings